



**LONDON
STOCK
EXCHANGE**

An LSEG Business

NS Strategy/Company/Operations Update

NXP001 UPDATE

[NUFORMIX PLC](#)

Released 07:00:05 18 September 2023

RNS Number : 6842M
Nuformix PLC
18 September 2023

18 September 2023

Nuformix plc

("Nuformix" or the "Company")

NXP001 Update

Nuformix receives new NXP001 development milestone payments in updated Oxilio agreement

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that the Company is to receive new immediate and near-term undisclosed milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd ("Oxilio").

Under the revised agreement with, Oxilio will acquire ownership of Nuformix's NXP001 patent estate, with Nuformix receiving the additional milestone payments referred to above, whilst retaining further development milestones and royalties capped at £2 million per year.

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: "Oxilio has a clear plan as to how NXP001 fits into their overall product development plan and we continue to fully support Oxilio in that process. The updated agreement has a dual benefit to Nuformix - we receive additional near-term cash payments, whilst discharging responsibility for future patent upkeep costs. The net positive impact on our cash position will better enable the Company to progress our core NXP002 and NXP004 programmes and respond to requests for additional data as we continue partnering interactions for these programmes."

Enquiries:

Nuformix plc

Dr Dan Gooding, Executive Director

Via IFC Advisory

Stanford Capital Partners Limited

Tom Price / Patrick Claridge (Corporate Finance)

+44 (0) 20 3650 3650

John Howes (Corporate Broking)

+44 (0) 20 3650 3652

IFC Advisory Limited

Tim Metcalfe

+44 (0) 20 3934 6630

Zach Cohen

nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lse.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDVDLFFXKLXBBK

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

© 2023 London Stock Exchange plc. All rights reserved.